x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Power to the Patients

Power to the Patients is a LinkedIn Live and podcast series hosted by Power where clinical research leaders across sponsors, sites, CROs, and patient advocacy groups discuss patient centricity in clinical trials. We explore the bottlenecks in today"s systems, challenge the status quo and talk about future opportunities for innovation. Looking for a clinical trial? Visit us at www.withpower.com

science life sciences

All Episodes

00:39:35

Backing Breakthroughs in Psychedelics

Power to the Patients ·

2025/06/06

Dina Burkitbayeva, CEO of Freedom Biosciences, shares how she launched one of the first venture funds focused on mental health innovation. After co-founding PsyMed Ventures, she partnered with Dr. John Krystal to advance a more durable version of ketamine for treatment-resistant depression. She discusses the rise of interventional psychiatry, the limitations of current antidepressants, and the evolving clinical landscape for next-gen therapeutics. A

en

00:47:26

Joel Raskin, CMO of Arrivo Bio talks about unlocking...

Power to the Patients ·

2025/05/23

Brandon Li talks with Joel Raskin, Chief Medical Officer at Arrivo, about his journey from training in psychiatry in Toronto to leading pharmaceutical research in his current role. Joel shares details on SP-624, an Arrivo compound showing promise in treating depression through epigenetic mechanisms. Their deep dive covers the challenges of clinical trials, and the potential for precision psychiatry to revolutionize psychiatry and neuroscience.

en

00:47:26

Joel Raskin, CMO of Arrivo Bio talks about unlocking...

Power to the Patients ·

2025/05/23

Brandon Li talks with Joel Raskin, Chief Medical Officer at Arrivo, about his journey from training in psychiatry in Toronto to leading pharmaceutical research in his current role. Joel shares details on SP-624, an Arrivo compound showing promise in treating depression through epigenetic mechanisms. Their deep dive covers the challenges of clinical trials, and the potential for precision psychiatry to revolutionize psychiatry and neuroscience.

en

47:26

Joel Raskin, CMO of Arrivo Bio talks about unlocking...

Power to the Patients ·

2025/05/23

Brandon Li talks with Joel Raskin, Chief Medical Officer at Arrivo, about his journey from training in psychiatry in Toronto to leading pharmaceutical research in his current role. Joel shares details on SP-624, an Arrivo compound showing promise in treating depression through epigenetic mechanisms. Their deep dive covers the challenges of clinical trials, and the potential for precision psychiatry to revolutionize psychiatry and neuroscience.

en

00:42:33

Dr. Jerry Rosenbaum & Dr. Sharmin Ghaznavi: Mass...

Power to the Patients ·

2025/05/12

In this episode, Dr. Jerry Rosenbaum and Dr. Sharmin Ghaznavi offer a rare look into academia’s role in the psychedelic renaissance, tracing the origins of Mass General’s Center for the Neuroscience of Psychedelics. They discuss how their shared interest in rumination—and its role in treatment-resistant mental illness—led them to explore psilocybin’s effects on brain connectivity. The conversation spans everything from neuroplasticity and default mode

en

00:42:33

Dr. Jerry Rosenbaum & Dr. Sharmin Ghaznavi: Mass...

Power to the Patients ·

2025/05/12

In this episode, Dr. Jerry Rosenbaum and Dr. Sharmin Ghaznavi offer a rare look into academia’s role in the psychedelic renaissance, tracing the origins of Mass General’s Center for the Neuroscience of Psychedelics. They discuss how their shared interest in rumination—and its role in treatment-resistant mental illness—led them to explore psilocybin’s effects on brain connectivity. The conversation spans everything from neuroplasticity and default mode

en

42:33

Dr. Jerry Rosenbaum & Dr. Sharmin Ghaznavi: Mass...

Power to the Patients ·

2025/05/12

In this episode, Dr. Jerry Rosenbaum and Dr. Sharmin Ghaznavi offer a rare look into academia’s role in the psychedelic renaissance, tracing the origins of Mass General’s Center for the Neuroscience of Psychedelics. They discuss how their shared interest in rumination—and its role in treatment-resistant mental illness—led them to explore psilocybin’s effects on brain connectivity. The conversation spans everything from neuroplasticity and default mode networks to the challenges of securing funding,

en

00:42:17

Spyros Papapetropoulos, CEO of Neuphoria

Power to the Patients ·

2025/05/12

Spyros Papapetropoulos, a leading neurologist and neuroscientist, joins Power CEO, Brandon Li, to discuss his remarkable career and the transformative work at Neuphoria. Spyros delves into his transition from practicing neurologist to drug development and his decision to focus on neuropsychiatric diseases. They explore Neuphoria's innovative approach to treating social anxiety disorder with their lead program, BNC210, which has shown promising results in

en

42:17

Spyros Papapetropoulos, CEO of Neuphoria

Power to the Patients ·

2025/05/12

Spyros Papapetropoulos, a leading neurologist and neuroscientist, joins Power CEO, Brandon Li, to discuss his remarkable career and the transformative work at Neuphoria. Spyros delves into his transition from practicing neurologist to drug development and his decision to focus on neuropsychiatric diseases. They explore Neuphoria's innovative approach to treating social anxiety disorder with their lead program, BNC210, which has shown promising results in reducing anxiety without the side effects of

en

00:41:13

Steve Gourlay, CEO of Actinogen

Power to the Patients ·

2025/04/28

Steve Gourlay joins Power CEO, Brandon Li, to discuss Actinogen's innovative approach to Alzheimer's treatment. Steven shares his background in clinical trials and drug development, highlighting the potential of the company's lead molecule, Xanamem, a daily pill aimed at reducing brain cortisol levels. Their conversation covers the challenges in Alzheimer's & depression research and the promising early clinical data. Steven sheds insight on the

en

00:41:13

Steve Gourlay, CEO of Actinogen

Power to the Patients ·

2025/04/28

Steve Gourlay joins Power CEO, Brandon Li, to discuss Actinogen's innovative approach to Alzheimer's treatment. Steven shares his background in clinical trials and drug development, highlighting the potential of the company's lead molecule, Xanamem, a daily pill aimed at reducing brain cortisol levels. Their conversation covers the challenges in Alzheimer's & depression research and the promising early clinical data. Steven sheds insight on the

en

41:13

Steve Gourlay, CEO of Actinogen

Power to the Patients ·

2025/04/28

Steve Gourlay joins Power CEO, Brandon Li, to discuss Actinogen's innovative approach to Alzheimer's treatment. Steven shares his background in clinical trials and drug development, highlighting the potential of the company's lead molecule, Xanamem, a daily pill aimed at reducing brain cortisol levels. Their conversation covers the challenges in Alzheimer's & depression research and the promising early clinical data. Steven sheds insight on the strategic focus on Alzheimer's over depression due to

en

00:40:32

Boehringer Ingelheim: Christine Sakdalan and Mike...

Power to the Patients ·

2025/04/09

In this episode of Power to the Patients, Boehringer Ingelheim leaders Christine Sakdalan and Mike Jablonski from discuss how precision psychiatry—using tools like biomarkers and neuroimaging—can personalize treatment for conditions like schizophrenia and depression. They highlight the importance of holistic care, digital therapeutics, and industry collaboration to address unmet needs and improve outcomes in mental health.

en

40:32

Boehringer Ingelheim: Christine Sakdalan and Mike...

Power to the Patients ·

2025/04/09

In this episode of Power to the Patients, Boehringer Ingelheim leaders Christine Sakdalan and Mike Jablonski from discuss how precision psychiatry—using tools like biomarkers and neuroimaging—can personalize treatment for conditions like schizophrenia and depression. They highlight the importance of holistic care, digital therapeutics, and industry collaboration to address unmet needs and improve outcomes in mental health.

en

00:40:32

Boehringer Ingelheim: Christine Sakdalan and Mike...

Power to the Patients ·

2025/04/09

In this episode of Power to the Patients, Boehringer Ingelheim leaders Christine Sakdalan and Mike Jablonski from discuss how precision psychiatry—using tools like biomarkers and neuroimaging—can personalize treatment for conditions like schizophrenia and depression. They highlight the importance of holistic care, digital therapeutics, and industry collaboration to address unmet needs and improve outcomes in mental health.

en

01:01:02

John Krystal: Advancing Ketamine Research &...

Power to the Patients ·

2025/03/07

John Krystal, Chair of the Department of Psychiatry at Yale, joins Brandon Li to discuss his groundbreaking work on ketamine's antidepressant effects and the evolving landscape of psychiatric treatments. Dr. Krystal was at the forefront of the discovery of ketamine's rapid antidepressant properties in the 1990s. Dr. Krystal shares insights from his career - his pioneering work on the rapid antidepressant effects of ketamine, exploring its journey from a

en

61:02

John Krystal: Advancing Ketamine Research &...

Power to the Patients ·

2025/03/07

John Krystal, Chair of the Department of Psychiatry at Yale, joins Brandon Li to discuss his groundbreaking work on ketamine's antidepressant effects and the evolving landscape of psychiatric treatments. Dr. Krystal was at the forefront of the discovery of ketamine's rapid antidepressant properties in the 1990s. Dr. Krystal shares insights from his career - his pioneering work on the rapid antidepressant effects of ketamine, exploring its journey from a misunderstood drug to a revolutionary

en

01:01:02

John Krystal: Advancing Ketamine Research &...

Power to the Patients ·

2025/03/07

John Krystal, Chair of the Department of Psychiatry at Yale, joins Brandon Li to discuss his groundbreaking work on ketamine's antidepressant effects and the evolving landscape of psychiatric treatments. Dr. Krystal was at the forefront of the discovery of ketamine's rapid antidepressant properties in the 1990s. Dr. Krystal shares insights from his career - his pioneering work on the rapid antidepressant effects of ketamine, exploring its journey from a misunderstood drug to a

en

00:45:01

Next-Gen Treatments for Anxiety and Depression Disorders

Power to the Patients ·

2025/02/25

In this episode, Brandon sits down with Shawn Singh, CEO of Vistagen, to discuss a first-of-its-kind approach to treating mental health conditions. Vistagen is developing pherines, a new class of nasal spray treatments that work through nose-to-brain neural pathways, with the potential to provide fast-acting relief for conditions like social anxiety disorder and depression—without systemic exposure, weight gain, or addiction risk. Key Takeaways: Mental health treatments haven’t

en

00:45:01

Next-Gen Treatments for Anxiety and Depression Disorders

Power to the Patients ·

2025/02/25

In this episode, Brandon sits down with Shawn Singh, CEO of Vistagen, to discuss a first-of-its-kind approach to treating mental health conditions. Vistagen is developing pherines, a new class of nasal spray treatments that work through nose-to-brain neural pathways, with the potential to provide fast-acting relief for conditions like social anxiety disorder and depression—without systemic exposure, weight gain, or addiction risk. Key Takeaways: Mental health treatments haven’t

en

108 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter